FindTrial
Sign In

Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI).

Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI). - Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032843
Enrollment
50
Registered
2018-06-02
Start date
2017-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

alirocumab75mg/2weeks for 32 to 40 weeks

Sponsors

Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with acute myocarial infarction having -Dyslipidemia undergoing treatment with HMG-CoA reductase inhibition -LDL-C 100 mg/dL or more in conventional therapy

Exclusion criteria

Exclusion criteria: -HMG-CoA reductase inhibitor is not used at the time of introduction -At the time of introduction of research drugs, patients with LDL-C less than 100 mg / dL -Contraindicated patients with HMG-CoA reductase inhibitors -Hypersensitivity to the study drug

Design outcomes

Primary

MeasureTime frame
assessment of myocardial remodering suppression effect after 32 to 40 weeks.—

Secondary

MeasureTime frame
assessment of coronary plaque imaging, serum biomarkers and coronary microcirculation after 32 to 40 weeks.—

Countries

Japan

Contacts

Public ContactHiroyasu Uzui

Faculty of Medical Sciences, University of Fukui Department of Cardiovascular Medicine

huzui@u-fukui.ac.jp0776-61-8800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026